Physician profile
Robert L Groat
NPI 1033135108
$3,212.08
in general payments reported to CMS, 2019-2025
24 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $393 · 2021: $540 · 2022: $634 · 2023: $462 · 2024: $341 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $545.71 | 2019-2022 | |
| Alcon Vision LLC | $374.35 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Abbvie INC. | $322.35 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $301.25 | 2019-2021 | |
| Oyster Point Pharma, INC. | $259.89 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $223.66 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Kala Pharmaceuticals, INC. | $209.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $204.24 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $140.15 | 2019-2020 | |
| Ocular Therapeutix, INC. | $113.22 | 2020 | |
| Apellis Pharmaceuticals, INC. | $102.22 | 2023 | Syfovre |
| Amgen INC. | $84.61 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $59.77 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $57.33 | 2021-2022 | |
| New World Medical,INC. | $35.07 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $29.57 | 2024 | Xdemvy |
| Akorn Operating Company LLC | $24.55 | 2021 | |
| Sight Sciences, INC. | $24.39 | 2025 | Omni Surgical System |
| Biotissue Holdings INC. | $22.50 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $18.06 | 2019 | |
| Harrow Eye, LLC | $13.96 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $13.30 | 2024 | |
| Omeros Corporation | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Groat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.